Nasdaq · Healthcare
LENSAR, Inc. (LNSR)
As-reported financials and recent SEC filings for LENSAR, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$51.7M
Net income
$-34.3M
Net margin
-66.4%
Diluted EPS
$-2.87
ROE
131.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $51.7M | $46.0M | $35.7M | $29.4M | $29.5M |
| Gross profit | $20.3M | $18.3M | $14.7M | $14.0M | $12.9M |
| Operating income | $-24.6M | $-10.7M | $-12.2M | $-20.2M | $-19.7M |
| Net income | $-34.3M | $-31.4M | $-14.4M | $-19.9M | $-19.6M |
| Diluted EPS | $-2.87 | $-2.73 | $-1.31 | $-1.96 | $-2.09 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
DEFA14A2026-06-23
View on EDGAR →ARS2026-06-23
View on EDGAR →DEF 14A2026-06-23
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Largest Healthcare peers
Go deeper on LNSR
Search LENSAR, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.